Compare Advance Auto Parts, Inc. (AAP) vs ACADIA Pharmaceuticals Inc. (ACAD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Advance Auto Parts, Inc. vs ACADIA Pharmaceuticals Inc. — how do they compare? Advance Auto Parts, Inc. trades at $53.12 (market cap $3.19B), while ACADIA Pharmaceuticals Inc. trades at $29.53 (market cap $5.07B). The key difference: ACADIA Pharmaceuticals Inc. is the larger of the two by market cap, and Advance Auto Parts, Inc. pays a 1.89% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| AAP | ACAD | |
|---|---|---|
Market Cap | $3.19B | $5.07B |
Sector | Consumer Cyclical | Health |
52-Week High | $64.17 | $29.41 |
52-Week Low | $38.75 | $20.06 |
Enterprise Value | $5.47B | $4.19B |
Dividend Yield | 1.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Advance Auto Parts (AAP) trades at $55.73, down 3.58% today, reflecting bearish technical signals amid mixed fundamentals. The company reported Q1 2026 EPS of $0.77, beating expectations, with revenue at $8.6 billion for 2025 but a slim net income margin of 0.51%. Recent news highlights restructuring efforts and AI-driven delivery initiatives to stabilize operations.
The outlook is cautious; while valuation ratios like P/S of 0.37 appear attractive, weak profitability and negative operating cash flow pose risks. Analyst consensus is mixed with a $61.30 price target, but high debt and competitive pressures require monitoring for sustained turnaround progress.
ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.
Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Advance Auto Parts, Inc.
Advance Auto Parts is one of the industry's largest retailers of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in North America. Advance operated 4,972 stores as of the end of 2021, in addition to servicing 1,317 independently owned Carquest stores. The company's Worldpac unit is a premier distributor of imported original-equipment parts. Advance derived 58% of its 2021 sales from commercial clients, up from 30%-40% before the General Parts deal.
Read more on AAP →About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →
